Randomized phase 1b/3 study of erlotinib plus ramucirumab in first-line EGFR mut + stage IV NSCLC: phase 1b safety results
Saved in:
Published in | Annals of oncology Vol. 28; p. vi56 |
---|---|
Main Authors | , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Elsevier Ltd
01.10.2017
|
Online Access | Get full text |
Cover
Loading…
ISSN: | 0923-7534 1569-8041 |
---|---|
DOI: | 10.1093/annonc/mdx426.005 |